The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
About Motif Bio,
Motif Bio has been reclassified as a cash shell and is not engaged in anything.........
About Motif Bio
Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP). Iclaprim exhibits potent activity against Gram-positive clinical isolates of various genera of staphylococci. It intends to build a portfolio of antibiotics by licensing drug candidates from organizations specializing in antibacterial research, and is pursuing programs in various stages of development.
WHO - have put a list together of a critical group that need new antibiotics against
multi drug resistant bacteria threat to hospitals, nursing homes and patients that care requires devices such as ventilators and blood catheters.
AMR fund priority - WHO/CDC priority list of pathogens
I genuinely try but I can't understand a word you say Danny.
We are all here on a whim and a prayer. Quite exciting but nerveracking. I've considered selling about godzillion times. My investment is my choice. I see the sales, dribs and drabs. But I look at the numbers. And think in order to buy, there is a price and round numbers give share numbers purchased. Look at the numbers sold, specifically!? If I'm wrong I will eat a Bobbie hat.
A few pints of scrumpy ?
What makes you say that joker?
Rather watch paint dry.....
BF did you get chance to catch up with come dine with me?
TOMORROW!!
Agreed Mark
It was more fun and engaging when it was all about potential suitors and the benefits or not of iclaprim ....
I don't think there's any point to prove here Darren, this BB was a lost cause months ago due to the lockdown and children not being able to go to school or University. Should be better in September (if we're still here with Motif) Just play along, it's quite a bit of fun some days. And who knows we may all make some money to boot. But not holding my breath...
https://twitter.com/Pfizer_UK/status/1283026798134071296?s=19 Just the $100M .
Plenty of money around to continue Iclaprim
What's your point Darren, if i did not post on here it would be like a virtual ghost town, i can't win when i post people moan, when i don't post posters are saying wheres BF.....
So i'm loathed when i post and missed when i don't, but GL with your investments/trades.......
Point proven.
Hi Trumpie, just finished slightly in the red
Seems a chatty guy! LOL!!!
Darren your second post since 2018 and that is your total input. Kettle black I think !
& 0.58 paid
Oh look at that, it's now 0.55p up on the day, someone must be nervous of losing their Summer job LOL. That's a real BIG BYE BYE ; )
I'm surprised most of you are oldl enough to trade looking at the chat on this board, it's like a school playground. Some of us check in to see if there has been any substantial news about the company but all we find is ( Im rubber you're glue nonsense. Grow up and focus on the company not each other ffs.
Question marks are not meant to be there. I put the thumbs up emoji at the end and it seems LSE does not like them
Another 1 mil buy. Even though they are using automatic trades to try and bring the price down.
I’m happy RTO is happening ????
Lol Nobice, just dropped after your #rattled run post....lol
Just got back from my afternoon jog, and pleasantly surprised the price is still 0.50p and way north of 0.20p